USE OF VEGF ANTAGONIST FOR THE THERAPEUTIC TREATMENT OF ANAGOGENETIC OCULAR DISORDERS

Abstract

The present invention provides methods for treating or preventing diabetic retinopathy. e.g., nonproliferative diabetic retinopathy, by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include administering 2 mg of aflibercept by intravitreal injection q8 weeks after three or five initial monthly doses (2q8) or 2 mg q16 weeks after three initial monthly doses and an 8-week interval (2q16). In addition. the present invention provides methods for reversing or halting the progression of NPDR to PDR (e.g., such that NPDR is reduced by 2 or 3 levels) or preventing the occurrence or recurrence of a vision-threatening complication by administering aflibercept according to the dosage regimens presented herein.